FindTrial
Sign In

Effect of QFR-guided Revascularization on 30-day mortality in Patients Undergoing Valve Surgery With Concomitant Coronary Artery Disease

Effect of QFR-guided Revascularization on 30-day mortality in Patients Undergoing Valve Surgery With Concomitant Coronary Artery Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017985
Enrollment
Unknown
Registered
2018-08-25
Start date
2018-10-30
Completion date
Unknown
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Contral:Angio-guided revascularization
Intervention:QFR-guided Revascularization

Sponsors

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years; 2. Inpatient indication for an elective valve surgery; 3. Concomitant significant CAD (at least one epicardial vessel with a stenosis> 50%); 4. Willing and able to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous CABG; 2. Planned PCI or CABG; 3. Secondary valvular disease; 4. Cardiogenic shock or any other clinical instability by the assisting physician; 5. Life expectancy < 12 months; 6. Currently participating in any other clinical trial.

Design outcomes

Primary

MeasureTime frame
30-day all cause-mortality rate;—

Secondary

MeasureTime frame
30-day MI rate;30-day stroke rate;30-day unplanned revascularization;30-day renal failure need dialysis rate;30-day CV mortality rate;—

Contacts

Public ContactYunpeng Zhu

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

zypB1014@rjh.com.cn+8613816819346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026